GAK and AAK1 inhibitor such as baricitinib have been wished for as a potential therapeutic agent for COVID-19 treatment by decreasing the viral entry, though no investigational work has been conducted to verify its mechanism of action [9]. The gene discussed is GAK; the disease is COVID-19.